Piper Sandler Reiterates Overweight on Biogen, Raises Price Target to $245

Benzinga · 1d ago
Piper Sandler analyst David Amsellem reiterates Biogen (NASDAQ:BIIB) with a Overweight and raises the price target from $225 to $245.